AtriCure, Inc. (ATRC) Financial Statements
AtriCure, Inc. (ATRC) reported trailing twelve-month revenue of $569.6M (up 13.9% year on year) and net income of $10.6M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $53.1M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ATRCAtriCure, Inc.Follow ATRC — free
—
Price chart with a free account
- Market cap
- 3.0B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 3 Nov, in 10 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 64.4 | 70.2 | 81.9 | 107.5 | 129.8 | 155.1 | 174.7 | 201.6 | 230.8 | 206.5 | 274.3 | 330.4 | 399.2 | 465.3 | 534.5 | 569.6 | |
| Gross profit | 47.0 | 50.0 | 59.6 | 75.8 | 92.9 | 111.1 | 126.2 | 147.1 | 170.3 | 149.3 | 205.9 | 245.9 | 300.4 | 347.5 | 400.8 | 434.6 | |
| Research & development | 11.9 | 12.1 | 13.4 | 18.6 | 25.7 | 35.8 | 34.1 | 34.7 | 41.2 | 43.1 | 48.5 | 57.3 | 73.9 | 96.2 | 99.2 | 98.0 | |
| Operating income | -4.7 | -7.2 | -10.9 | -16.4 | -26.7 | -31.1 | -25.0 | -17.1 | -33.1 | -44.2 | 55.2 | -42.7 | -26.7 | -40.0 | -9.4 | 12.9 | |
| Pre-tax income | -5.4 | -7.5 | -11.4 | -16.2 | -27.2 | -33.3 | -26.9 | -20.9 | -35.0 | -48.0 | 50.4 | -46.2 | -29.8 | -43.7 | -10.2 | 12.1 | |
| Income tax | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.2 | 0.1 | 0.2 | 0.3 | 0.6 | 1.0 | 1.3 | 1.5 | |
| Net income | -5.5 | -7.5 | -11.5 | -16.2 | -27.2 | -33.3 | -26.9 | -21.1 | -35.2 | -48.2 | 50.2 | -46.5 | -30.4 | -44.7 | -11.4 | 10.6 | |
| Diluted EPS ($) | -0.35 | -0.47 | -0.56 | -0.61 | -0.97 | -1.05 | -0.83 | -0.62 | -0.94 | -1.14 | 1.09 | -1.02 | -0.66 | -0.95 | -0.24 | 0.21 | |
| Diluted shares (mn) | — | — | — | — | — | — | — | — | — | — | 46.0 | 45.7 | 46.3 | 47.0 | 47.8 | — |
USD millions · SEC XBRL
AtriCure, Inc. — questions
- What is AtriCure, Inc.'s revenue?
- $569.6M over the twelve months to 2026-06-30, up 13.9% year on year, from its 10-Q and 10-K filings.
- What is AtriCure, Inc.'s net income?
- $10.6M over the twelve months to 2026-06-30.
- What is AtriCure, Inc.'s free cash flow?
- $53.1M over the twelve months to 2026-06-30.
- What are AtriCure, Inc.'s diluted earnings per share?
- $0.21 over the twelve months to 2026-06-30.
Every figure on this page comes from AtriCure, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.